Copanlisib (BAY 80-6946)

Catalog No.S2802

Copanlisib (BAY 80-6946) Chemical Structure

Molecular Weight(MW): 480.52

Copanlisib (BAY 80-6946) is a potent pan-class I PI3K with IC50 of 0.5, 3.7, 6.4, and 0.7 nM in cell-free assays for PI3Kα/β/γ/δ , respectively. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 6 Publications

3 Customer Reviews

  • The compounds BAY80-6946 and TG100713, which are respectively an alpha/beta- and a pan-isoforms inhibitors, demonstrated a very good ability to block Jurkat E6.1 proliferation with an IC50 slightly higher than 1 mM.

    Dr. Antonino Maria Spartà from University of Bolog. Copanlisib (BAY 80-6946) purchased from Selleck.

    PI3K inhibitor BAY 80-6946 demonstrated to be effective on ALL-SIL cells,showed an IC50 in the lower micromolar range.

    Dr. Antonino Maria Spartà from University of Bolog. Copanlisib (BAY 80-6946) purchased from Selleck.

  • (A) Total cell lysates were immunoblotted with the indicated antibodies. β-actin served as the loading control.

    Oncol Rep, 2017, 37(5):3137-3145. Copanlisib (BAY 80-6946) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Copanlisib (BAY 80-6946) is a potent pan-class I PI3K with IC50 of 0.5, 3.7, 6.4, and 0.7 nM in cell-free assays for PI3Kα/β/γ/δ , respectively. Phase 3.
Targets
PI3Kα [1]
(Cell-free assay)
PI3Kδ [1]
(Cell-free assay)
PI3Kβ [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
0.5 nM 0.7 nM 3.7 nM 6.4 nM
In vitro

In both KPL4 cells and LPA-stimulated PC3 cells, BAY 80-6946 reduces pAKT levels. In a subset of human cancer cell lines with PIK3CA mutations and/or overexpression of HER2, BAY 80-6946 shows antiproliferative activity and induces apoptosis. [1] The combination of HER2-targeted therapies and BAY 80-6946 inhibits growth more effectively than either therapy used alone, and can restore sensitivity to trastuzumab and lapatinib in cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Huh7 NVvtUow4T3Kxd4ToJIlvcGmkaYTvckBie3OjeR?= MXexNFAhdk1? NXW3V5l3S2:yYX7sbZNq[iCmb4PlMYRmeGWwZHXueIx6KGmwaHnibZRm\CClZXzsJIdzd3e2aDDpckB3cXS{bz6gTWM2OD12Nz65JI5ONg>? Ml23N|A6PjJ7NUK=
HepG2 MkjmS5Jwf3SqIHnubIljcXSxbjDhd5NigQ>? M{\DNFExOCCwTR?= MlzzR49x[W6uaYPpZkBld3OnLXTldIVv\GWwdHz5JIlvcGmkaYTl[EBk\WyuIHfyc5d1cCCrbjD2bZRzdy5iSVO1NF0{OS54IH7NMi=> M2i0eFMxQTZ{OUWy
Hep3B M2W0dGdzd3e2aDDpcohq[mm2b36gZZN{[Xl? MV7JR|UxRTd{LkSgcm0> MlrxN|A6PjJ7NUK=
PLCPRF5 MVnHdo94fGhiaX7obYJqfG:wIHHzd4F6 NH65UYxKSzVyPUK4N{BvVQ>? MoK2N|A6PjJ7NUK=
Chang MoPlS5Jwf3SqIHnubIljcXSxbjDhd5NigQ>? MUPJR|UxRTR2MjDuUS=> M1\WOFMxQTZ{OUWy
JVM-3 NXPTb2MxTnWwY4Tpc44h[XO|YYm= MnjYOFghcA>? NV25bVZJcW6qaXLpeJMhdWW2YXLvcIlkKGGldHn2bZR6KHerdHigZY4hUUN3MDDv[kAzKM7:TTDpckB1cGViWGTUJIF{e2G7 MXyyOVkyOjZ|NR?=
BT-474 NYG3RmRiTnWwY4Tpc44h[XO|YYm= NYDwPJJSPTBibl2= M1\Qb|AvPSxiMjygOEwhQCxiMkSgbC=> NXryS4xNemGyaXTsfUBqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApWzR5MzygWFMxQCliYYOge4VtdCCjczDpeJMh\Gm{ZXP0JJN2[nO2cnH0[ZMhWFKDU{SwJEhVOjR4KTDhcoQhT1ONM98yJEhUQSluIHHu[EBqdmirYnn0bY9vKHejczDzeZN1[WmwZXSg[o9zKHWyIITvJFI1KGixdYLz MmHqNlQ1OzZyNEi=
SK-BR-3 NFrWc3JHfW6ldHnvckBie3OjeR?= Mor3NEwhOSxiMjygOEBp NGfvfpRld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= MYqyOFQ{PjB2OB?=
UACC-893 MnGwSpVv[3Srb36gZZN{[Xl? NWm5TGdlOCxiMTygNkwhPCCq M3f2coRwf26{ZXf1cIF1cW:wIH;mJHAuSUuW MoPCNlQ1OzZyNEi=
HCC-1954 M{HOWGZ2dmO2aX;uJIF{e2G7 MWCwMEAyNCB{LDC0JIg> NVf1W4VL\G:5boLl[5Vt[XSrb36gc4YhWC2DS2S= NEPyPYgzPDR|NkC0PC=>
MDA-MB-453 MmnvSpVv[3Srb36gZZN{[Xl? MmnDNEwhOSxiMjygOEBp Ml;x[I94dnKnZ4XsZZRqd25ib3[gVE1CU1R? MUOyOFQ{PjB2OB?=
MDA-MB-361 MVrGeY5kfGmxbjDhd5NigQ>? MWqwMEAyNCB{LDC0JIg> MWjkc5dvemWpdXzheIlwdiCxZjDQMWFMXA>? NHX2b5gzPDR|NkC0PC=>
BT-20 NF7GbZVHfW6ldHnvckBie3OjeR?= NGLw[4IxNCBzLDCyMEA1KGh? NYDEcpBv\G:5boLl[5Vt[XSrb36gc4YhWC2DS2S= M17RZVI1PDN4MES4
MCF-7 M3LnWWZ2dmO2aX;uJIF{e2G7 M1LsSFAtKDFuIEKsJFQhcA>? Mnfz[I94dnKnZ4XsZZRqd25ib3[gVE1CU1R? MVmyOFQ{PjB2OB?=
T-47D NHTWclBHfW6ldHnvckBie3OjeR?= M1m1XlAtKDFuIEKsJFQhcA>? MkLD[I94dnKnZ4XsZZRqd25ib3[gVE1CU1R? MnTuNlQ1OzZyNEi=
HCC1806 NWXMOZRETnWwY4Tpc44h[XO|YYm= NWH3bWlLOCxiMTygNkwhPCCq MX3kc5dvemWpdXzheIlwdiCxZjDQMWFMXA>? NVq5fGJGOjR2M{[wOFg>
NCI-H292 M1vtOWZ2dmO2aX;uJIF{e2G7 NYO4PVJNOCxiMTygNkwhPCCq NH\aW4hld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= NXvDVJJROjR2M{[wOFg>
NCI-H1650 M2PC[mZ2dmO2aX;uJIF{e2G7 NV;KbpI6OCxiMTygNkwhPCCq NUS3d|Fo\G:5boLl[5Vt[XSrb36gc4YhWC2DS2S= MmnRNlQ1OzZyNEi=
CCRF-SB MnzrSpVv[3Srb36gZZN{[Xl? NIH1eFExNCBzLDCyMEA1KGh? NHyxXGZld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= MXiyOFQ{PjB2OB?=
U937 NGHKd|FHfW6ldHnvckBie3OjeR?= M3XtNlAtKDFuIEKsJFQhcA>? MV\kc5dvemWpdXzheIlwdiCxZjDQMWFMXA>? NXPi[ppnOjR2M{[wOFg>
SU-DHL-4 MY\GeY5kfGmxbjDhd5NigQ>? MUWwMEAyNCB{LDC0JIg> MXPkc5dvemWpdXzheIlwdiCxZjDQMWFMXA>? NFjjO48zPDR|NkC0PC=>
SU-DHL-5 NFnFOGFHfW6ldHnvckBie3OjeR?= NVfLbYZxOCxiMTygNkwhPCCq NE\p[5lld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= NYTGZ5ZsOjR2M{[wOFg>
HCT116 NVLienl1TnWwY4Tpc44h[XO|YYm= Ml7mNEwhOSxiMjygOEBp M1\PTYRwf26{ZXf1cIF1cW:wIH;mJHAuSUuW Ml[4NlQ1OzZyNEi=
A549 cells NGfjc2JHfW6ldHnvckBie3OjeR?= M3vpcVAtKDFuIEKsJFQhcA>? MnrJ[I94dnKnZ4XsZZRqd25ib3[gVE1CU1R? MofjNlQ1OzZyNEi=
SK-MEL-30 NWTxSllPTnWwY4Tpc44h[XO|YYm= M2XD[|AtKDFuIEKsJFQhcA>? MnHH[I94dnKnZ4XsZZRqd25ib3[gVE1CU1R? MnfRNlQ1OzZyNEi=
SK-MEL-2 cells NUPI[nVUTnWwY4Tpc44h[XO|YYm= NUHVZ25KOCxiMTygNkwhPCCq NEnvcXpld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= MXWyOFQ{PjB2OB?=
NCI-H1703 Mm\5SpVv[3Srb36gZZN{[Xl? M2nYXlAtKDFuIEKsJFQhcA>? NGfrTYFld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= MVqyOFQ{PjB2OB?=
NCI-H661 NYjmV5dETnWwY4Tpc44h[XO|YYm= NEjyZ4wxNCBzLDCyMEA1KGh? NGG2TYJld3ewcnXneYxifGmxbjDv[kBRNUGNVB?= MoHJNlQ1OzZyNEi=
PC9 NXLFTHU2TnWwY4Tpc44h[XO|YYm= MW[wMEAyNCB{LDC0JIg> MXjkc5dvemWpdXzheIlwdiCxZjDQMWFMXA>? NYLLbpV1OjR2M{[wOFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-PRAS40(T246) / p-GSK3β(S9) / cleaved caspase-3 / cleaved caspase-7 / PI3K-p85; 

PubMed: 24436048     


BT-474 cells were treated with BAY 80-6946 (50nM) or MK2206 (2μM) and collected at indicated times. Immunoblots of AKT, AKT substrates, and surrogates for apoptosis show similar AKT inhibition but greater apoptosis with PI3K inhibition.

p-FoxO4(T28) / p-S6(S235/236) / p-4E-BP1(S65) / p-4E-BP1(T37/46) / p-HER3(Y1197) / HER3 / p-IGF1Rβ/ IGF1R / p-HER2 / p-EGFR / p-STAT3 / p-ERK; 

PubMed: 24436048     


BT-474 cells were treated with BAY 80-6946 (50nM) or MK2206 (2μM) and collected at indicated times. Immunoblots of AKT and mTOR substrates, RTKs, and parallel pathways like STAT and ERK.

24436048
Growth inhibition assay
Cell viability; 

PubMed: 24436048     


BT-474 cells were treated with DMSO, MK2206 (2μM), or BAY 80-6946 (50nM) and viable cells were counted at indicated times, demonstrating loss in viable cell number with PI3K inhibition. Results were reported as a mean of triplicate with standard errors.

24436048
In vivo In rat KPL4 or HCT116 tumor xenograft model, BAY 80-6946 (6 mg/kg, i.v.) induces 100% complete tumor regression. In nude mice with Lu7860 erlotinib-resistant, patient-derived NSCLC and MAXF1398 patient-derived luminal breast tumor models, BAY 80-6946 (14 mg/kg, i.v.) also causes tumor growth inhibition. [1]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical lipid kinase assays:

The effect of BAY 80-6946 on PI3Kα, PI3Kβ, and PI3Kγ activity is measured by the inhibition of 33P incorporation into phosphatidylinositol (PI) in 384-well MaxiSorp® plates coated with 2 µg/well of PI and phosphatidylserine (PS) (1:1 molar ratio). In each PI3K isoform assay, 9 µL of reaction buffer (50 mM MOPSO, pH 7.0, 100 mM NaCl, 4 mM MgCl2, 0.1% BSA) containing 7.5 ng of His-tagged N-terminal truncated p110α or p110β protein, or 25 ng of purified human p110γ protein, is used. The reaction is started by adding 5 µL of a 40-µM ATP solution containing 20 µCi/mL [33>/sup>P]-ATP. After 2 hours incubation at room temperature, the reaction is terminated by addition of 5 µL of a 25-mM EDTA solution. The plates are washed and Ultima Gold™ scintillation cocktail (25 µL) is then added. The radioactivity incorporated into the immobilized PI substrate is determined with a BetaPlate Liquid Scintillation Counter.
Cell Research:[1]
+ Expand
  • Cell lines: A series of cancer cell lines
  • Concentrations: ~5 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation over a 72-hour period is determined using the CellTiter-Glo® luminescent cell viability kit. Briefly, cells are plated in separate microtiter plates. Following an overnight incubation at 37ºC, luminescence values in the t=0 hour plates are determined. Test compounds diluted in growth medium are added to the t=72 hour plates, and the cells are then incubated for 72 hours at 37ºC. Luminescence values are determined with a Wallac 1420 Victor2™ 1420 multilabel HTS counter after a 10-minute reaction with CellTiter-Glo® solution. The percentage inhibition of cell growth is calculated by subtracting the luminescence values in the t=0 hour plates from the corresponding values in the t=72 hour plates. Differences in values between drug-treated cells and controls are used to determine the percentage inhibition of cell growth.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Rats bearing KPL4 or HCT116 xenografts
  • Formulation: PEG400/acidified water (0.1 N HCl, pH 3.5; 20/80, v/v) or 5% mannitol
  • Dosages: 6 mg/kg
  • Administration: i.v.
    (Only for Reference)

Solubility (25°C)

In vitro 10% Trifluoroacetic acid water solution 1 mg/mL (2.08 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMSO 0.002 mg/mL (0.0 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
10% Trifluoroacetic acid water solution
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.52
Formula

C23H28N8O4

CAS No. 1032568-63-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03842228 Not yet recruiting Advanced Malignant Solid Neoplasm|ARID1A Gene Mutation|ATM Gene Mutation|ATRX Gene Mutation|BARD1 Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|BRIP1 Gene Mutation|CDK12 Gene Mutation|CHEK1 Gene Mutation|CHEK2 Gene Mutation|FANCA Gene Mutation|FANCL Gene Mutation|Metastatic Malignant Solid Neoplasm|MRE11 Gene Mutation|MSH2 Gene Mutation|PALB2 Gene Mutation|PARP1 Gene Mutation|PIK3CA Gene Mutation|POLD1 Gene Mutation|PPP2R2A Gene Mutation|PTEN Gene Mutation|RAD51B Gene Mutation|RAD51C Gene Mutation|RAD51D Gene Mutation|RAD54L Gene Mutation|Unresectable Malignant Solid Neoplasm|XRCC2 Gene Mutation National Cancer Institute (NCI) June 10 2019 Phase 1
NCT03886649 Not yet recruiting Non-Hodgkin Lymphoma Swiss Group for Clinical Cancer Research June 2019 Phase 1
NCT03842228 Not yet recruiting Advanced Malignant Solid Neoplasm|ARID1A Gene Mutation|ATM Gene Mutation|ATRX Gene Mutation|BARD1 Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|BRIP1 Gene Mutation|CDK12 Gene Mutation|CHEK1 Gene Mutation|CHEK2 Gene Mutation|FANCA Gene Mutation|FANCL Gene Mutation|Metastatic Malignant Solid Neoplasm|MRE11 Gene Mutation|MSH2 Gene Mutation|PALB2 Gene Mutation|PARP1 Gene Mutation|PIK3CA Gene Mutation|POLD1 Gene Mutation|PPP2R2A Gene Mutation|PTEN Gene Mutation|RAD51B Gene Mutation|RAD51C Gene Mutation|RAD51D Gene Mutation|RAD54L Gene Mutation|Unresectable Malignant Solid Neoplasm|XRCC2 Gene Mutation National Cancer Institute (NCI) June 10 2019 Phase 1
NCT03886649 Not yet recruiting Non-Hodgkin Lymphoma Swiss Group for Clinical Cancer Research June 2019 Phase 1
NCT03877055 Recruiting Mantle Cell Lymphoma (MCL) Memorial Sloan Kettering Cancer Center|Bayer March 13 2019 Phase 1|Phase 2
NCT03789240 Not yet recruiting Follicular Lymphoma|Non-Hodgkin''s Lymphoma|NHL National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 28 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    S2802 (BAY 80-6946) has poor solubility in DMSO and water. Do you have any other suggestion to dissolve this chemical?

  • Answer:

    We've tested the solubility of S2802 BAY80-6946 in dichloromethane, chloroform, acetonitrile, acetone, tetrahydrofuran and TFA (aq), and finally found it can be dissolved in 10% Trifluoroacetic acid water solution at 1 mg/ml as a clear solution.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Copanlisib (BAY 80-6946) | Copanlisib (BAY 80-6946) supplier | purchase Copanlisib (BAY 80-6946) | Copanlisib (BAY 80-6946) cost | Copanlisib (BAY 80-6946) manufacturer | order Copanlisib (BAY 80-6946) | Copanlisib (BAY 80-6946) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID